[{"id":"9f749ec0-9a4e-415b-87ef-80069ba67c42","acronym":"MA-CRC-II-018","url":"https://clinicaltrials.gov/study/NCT07478731","created_at":"2026-03-28T01:41:18.497Z","updated_at":"2026-03-28T01:41:18.497Z","phase":"Phase 2","brief_title":"Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer","source_id_and_acronym":"NCT07478731 - MA-CRC-II-018","lead_sponsor":"Hong Qiu","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e retlirafusp alfa (SHR-1701)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 12/20/2025","start_date":" 12/20/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2026-03-17"},{"id":"a9f39237-1737-4421-910a-0e37d38262b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05083754","created_at":"2023-11-27T22:14:37.322Z","updated_at":"2025-02-25T12:28:25.580Z","phase":"Phase 1","brief_title":"Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma","source_id_and_acronym":"NCT05083754","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1 • MSI • CD8 • PD-1 • CD4 • ICOS","pipe":"","alterations":" ","tags":["PD-L1 • MSI • CD8 • PD-1 • CD4 • ICOS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • carmustine • Zynyz (retifanlimab-dlwr)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-24"},{"id":"c79faf97-f729-4398-957b-5d83e409d779","acronym":"COMMIT","url":"https://clinicaltrials.gov/study/NCT02997228","created_at":"2021-01-18T14:45:08.921Z","updated_at":"2025-02-25T12:26:35.429Z","phase":"Phase 3","brief_title":"Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study","source_id_and_acronym":"NCT02997228 - COMMIT","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • MSI-H/dMMR","tags":["PD-L1 • MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 01/19/2018","start_date":" 01/19/2018","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-24"},{"id":"f49513f4-2324-4f1a-bfa6-fcc569055fc2","acronym":"STAR-T","url":"https://clinicaltrials.gov/study/NCT05839951","created_at":"2023-05-03T15:04:35.012Z","updated_at":"2025-02-25T12:29:31.860Z","phase":"","brief_title":"An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions","source_id_and_acronym":"NCT05839951 - STAR-T","lead_sponsor":"Bayer","biomarkers":" KRAS • MSI","pipe":"","alterations":" ","tags":["KRAS • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 04/24/2023","start_date":" 04/24/2023","primary_txt":" Primary completion: 03/14/2025","primary_completion_date":" 03/14/2025","study_txt":" Completion: 03/14/2025","study_completion_date":" 03/14/2025","last_update_posted":"2025-02-24"},{"id":"668fd5a3-2595-4b5e-9008-d986e7e3501e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05078866","created_at":"2021-10-15T15:53:08.571Z","updated_at":"2025-02-25T13:40:39.704Z","phase":"Phase 1/2","brief_title":"Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients","source_id_and_acronym":"NCT05078866","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NOUS-209"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 11/10/2022","start_date":" 11/10/2022","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2025-02-21"},{"id":"722e7e39-2b2e-4e81-be40-58b1e321be96","acronym":"","url":"https://clinicaltrials.gov/study/NCT06043713","created_at":"2023-09-21T15:10:30.740Z","updated_at":"2025-02-25T13:41:44.027Z","phase":"Phase 1","brief_title":"Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations","source_id_and_acronym":"NCT06043713","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK","pipe":" | ","alterations":" KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion","tags":["HER-2 • KRAS • BRAF • ALK • TMB • MSI • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • TMB-H • BRAF mutation • HER-2 amplification • ROS1 fusion • KRAS G12 • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 12/15/2023","start_date":" 12/15/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 02/09/2026","study_completion_date":" 02/09/2026","last_update_posted":"2025-02-21"},{"id":"8100f49e-ecbc-41b2-9130-5ed625da8fc7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04669496","created_at":"2025-02-25T13:40:17.235Z","updated_at":"2025-02-25T13:40:17.235Z","phase":"Phase 2/3","brief_title":"Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma with High-risk Recurrence Factors","source_id_and_acronym":"NCT04669496","lead_sponsor":"Shanghai Zhongshan Hospital","biomarkers":" TMB • MSI • CEACAM5 • MUC16","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB • MSI • CEACAM5 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi) • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 178","initiation":"Initiation: 01/20/2021","start_date":" 01/20/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-21"},{"id":"d0e8c003-1353-4bf0-ae65-13236586de27","acronym":"AIM-NIVO","url":"https://clinicaltrials.gov/study/NCT03816345","created_at":"2021-01-18T18:51:20.043Z","updated_at":"2025-02-25T13:39:45.299Z","phase":"Phase 1","brief_title":"Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer","source_id_and_acronym":"NCT03816345 - AIM-NIVO","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • IL2","pipe":"","alterations":" ","tags":["MSI • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 07/16/2019","start_date":" 07/16/2019","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-02-21"},{"id":"e17de7f3-6ed2-44ac-8c1d-acf78b25a29e","acronym":"NCI-2017-02296","url":"https://clinicaltrials.gov/study/NCT03375307","created_at":"2021-01-18T16:39:30.359Z","updated_at":"2025-02-25T13:39:36.028Z","phase":"Phase 2","brief_title":"Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes","source_id_and_acronym":"NCT03375307 - NCI-2017-02296","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC","pipe":" | ","alterations":" FANCG mutation","tags":["TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FANCG mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 11/03/2020","start_date":" 11/03/2020","primary_txt":" Primary completion: 12/16/2025","primary_completion_date":" 12/16/2025","study_txt":" Completion: 12/16/2025","study_completion_date":" 12/16/2025","last_update_posted":"2025-02-21"},{"id":"0cde78dd-3c84-4aec-a573-c0c0e01915a1","acronym":"OPTEC","url":"https://clinicaltrials.gov/study/NCT03460483","created_at":"2021-01-18T17:03:29.688Z","updated_at":"2025-02-25T13:48:28.789Z","phase":"","brief_title":"Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care","source_id_and_acronym":"NCT03460483 - OPTEC","lead_sponsor":"Ohio State University Comprehensive Cancer Center","biomarkers":" MSI • POLE","pipe":" | ","alterations":" POLE mutation","tags":["MSI • POLE"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e POLE mutation"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1001","initiation":"Initiation: 03/30/2018","start_date":" 03/30/2018","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2025-02-20"},{"id":"34e7c443-a4b5-4fa2-810c-e931f9bf2ab9","acronym":"SGNEGFRd2-001","url":"https://clinicaltrials.gov/study/NCT05983133","created_at":"2023-08-09T14:09:24.911Z","updated_at":"2025-02-25T13:55:26.636Z","phase":"Phase 1","brief_title":"A Study of SGN-EGFRd2 in Advanced Solid Tumors","source_id_and_acronym":"NCT05983133 - SGNEGFRd2-001","lead_sponsor":"Seagen Inc.","biomarkers":" EGFR • ALK • MSI","pipe":" | ","alterations":" EGFR mutation • MSI-H/dMMR • ALK rearrangement","tags":["EGFR • ALK • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MSI-H/dMMR • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PF-08046052"],"overall_status":"Recruiting","enrollment":" Enrollment 275","initiation":"Initiation: 11/14/2023","start_date":" 11/14/2023","primary_txt":" Primary completion: 07/31/2027","primary_completion_date":" 07/31/2027","study_txt":" Completion: 09/30/2028","study_completion_date":" 09/30/2028","last_update_posted":"2025-02-20"},{"id":"4405fdfb-3952-4954-a472-701ca7d88a54","acronym":"","url":"https://clinicaltrials.gov/study/NCT05821777","created_at":"2023-04-20T14:03:54.395Z","updated_at":"2025-02-25T13:49:46.186Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants with Advanced Solid Tumors","source_id_and_acronym":"NCT05821777","lead_sponsor":"Centessa Pharmaceuticals (UK) Limited","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e itanistomig (LB101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/28/2023","start_date":" 03/28/2023","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 01/05/2027","study_completion_date":" 01/05/2027","last_update_posted":"2025-02-20"},{"id":"5b604fcd-b187-4ac2-8cb5-8e6c3fc1616c","acronym":"CheckMate 8KX","url":"https://clinicaltrials.gov/study/NCT03656718","created_at":"2021-01-18T17:56:53.970Z","updated_at":"2025-02-25T13:52:39.029Z","phase":"Phase 1/2","brief_title":"A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)","source_id_and_acronym":"NCT03656718 - CheckMate 8KX","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)"],"overall_status":"Completed","enrollment":" Enrollment 139","initiation":"Initiation: 10/29/2018","start_date":" 10/29/2018","primary_txt":" Primary completion: 09/07/2022","primary_completion_date":" 09/07/2022","study_txt":" Completion: 09/12/2024","study_completion_date":" 09/12/2024","last_update_posted":"2025-02-20"},{"id":"53c57014-eed8-45c6-afa4-43da3ec376e4","acronym":"BGB-A317-214","url":"https://clinicaltrials.gov/study/NCT05116085","created_at":"2021-11-10T14:13:08.209Z","updated_at":"2025-02-25T14:08:28.217Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer","source_id_and_acronym":"NCT05116085 - BGB-A317-214","lead_sponsor":"BeiGene","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 01/26/2022","start_date":" 01/26/2022","primary_txt":" Primary completion: 09/26/2023","primary_completion_date":" 09/26/2023","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-18"},{"id":"ed7e0a8d-7121-41ed-982b-5af9f5bc5b3a","acronym":"NRG-GY025","url":"https://clinicaltrials.gov/study/NCT05112601","created_at":"2021-11-09T20:21:18.547Z","updated_at":"2025-02-25T14:16:28.432Z","phase":"Phase 2","brief_title":"Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma","source_id_and_acronym":"NCT05112601 - NRG-GY025","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 06/02/2022","start_date":" 06/02/2022","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2025-02-18"},{"id":"03ad2ae1-62eb-4ee9-9973-fa23d5f2634d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05904496","created_at":"2023-06-15T17:08:23.801Z","updated_at":"2025-02-25T14:18:02.487Z","phase":"Phase 1","brief_title":"A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05904496","lead_sponsor":"BeiGene","biomarkers":" TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • BGB-30813"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/19/2023","start_date":" 07/19/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-17"},{"id":"2c844ff3-38e3-4e1a-ab45-51650b975490","acronym":"ST316-101","url":"https://clinicaltrials.gov/study/NCT05848739","created_at":"2023-05-08T15:04:02.971Z","updated_at":"2025-02-25T14:17:54.068Z","phase":"Phase 1","brief_title":"A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors","source_id_and_acronym":"NCT05848739 - ST316-101","lead_sponsor":"Sapience Therapeutics","biomarkers":" PD-L1 • MSI • BRCA","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR • BRCA mutation","tags":["PD-L1 • MSI • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • irinotecan • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil) • leucovorin calcium • ST316"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 06/05/2023","start_date":" 06/05/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2025-02-17"},{"id":"59d4a003-e862-4682-ad7b-ffa3cb7e3e25","acronym":"","url":"https://clinicaltrials.gov/study/NCT03190174","created_at":"2021-01-18T15:43:45.733Z","updated_at":"2025-02-25T14:15:01.560Z","phase":"Phase 1/2","brief_title":"Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers","source_id_and_acronym":"NCT03190174","lead_sponsor":"Sarcoma Oncology Research Center, LLC","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • sirolimus • Fyarro (nanoparticle albumin-bound rapamycin)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 08/24/2017","start_date":" 08/24/2017","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/02/2021","study_completion_date":" 12/02/2021","last_update_posted":"2025-02-17"},{"id":"6553092f-70e4-434d-af85-c9de431dfb02","acronym":"","url":"https://clinicaltrials.gov/study/NCT03290937","created_at":"2021-01-18T16:15:28.855Z","updated_at":"2025-02-25T14:07:03.272Z","phase":"Phase 1","brief_title":"Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03290937","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR • RAS mutation","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • irinotecan • utomilumab (PF-05082566) • Datalai (cetuximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 12/27/2017","start_date":" 12/27/2017","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-17"},{"id":"742fd153-ce97-4ee4-b30a-065c666ab97f","acronym":"UNICORN","url":"https://clinicaltrials.gov/study/NCT05845450","created_at":"2023-05-06T15:04:38.828Z","updated_at":"2025-02-25T14:09:41.563Z","phase":"Phase 2","brief_title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","source_id_and_acronym":"NCT05845450 - UNICORN","lead_sponsor":"Gruppo Oncologico del Nord-Ovest","biomarkers":" HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1","pipe":" | ","alterations":" HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type","tags":["HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Vectibix (panitumumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)"],"overall_status":"Recruiting","enrollment":" Enrollment 112","initiation":"Initiation: 05/11/2023","start_date":" 05/11/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2028","study_completion_date":" 05/01/2028","last_update_posted":"2025-02-17"},{"id":"9e066b71-7f4b-4632-8ecf-e6e2e35a7dd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05427487","created_at":"2022-06-22T21:54:15.197Z","updated_at":"2025-02-25T14:08:55.980Z","phase":"Phase 1","brief_title":"Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours","source_id_and_acronym":"NCT05427487","lead_sponsor":"ImmVirx Pty Ltd","biomarkers":" MSI","pipe":"","alterations":" ","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • IVX037"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 02/17/2023","start_date":" 02/17/2023","primary_txt":" Primary completion: 09/30/2026","primary_completion_date":" 09/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2025-02-17"},{"id":"b24e71ea-fdd0-4abb-be7e-df7c10fbc959","acronym":"BEGIN","url":"https://clinicaltrials.gov/study/NCT06272864","created_at":"2024-02-22T17:27:27.414Z","updated_at":"2025-02-25T14:10:41.690Z","phase":"","brief_title":"BostonGene and Exigent Genomic INsight Study","source_id_and_acronym":"NCT06272864 - BEGIN","lead_sponsor":"BostonGene","biomarkers":" TMB • MSI","pipe":"","alterations":" ","tags":["TMB • MSI"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 04/08/2024","start_date":" 04/08/2024","primary_txt":" Primary completion: 01/08/2026","primary_completion_date":" 01/08/2026","study_txt":" Completion: 01/08/2028","study_completion_date":" 01/08/2028","last_update_posted":"2025-02-17"},{"id":"4ef750b4-3fb6-4689-b95f-2c678d9c99e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04777994","created_at":"2021-03-02T12:52:26.138Z","updated_at":"2025-02-25T14:40:45.849Z","phase":"Phase 1","brief_title":"Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors","source_id_and_acronym":"NCT04777994","lead_sponsor":"AbbVie","biomarkers":" PD-L1 • MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1 • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e osunprotafib (ABBV-CLS-484)"],"overall_status":"Recruiting","enrollment":" Enrollment 248","initiation":"Initiation: 03/09/2021","start_date":" 03/09/2021","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-02-14"},{"id":"8e80751c-1262-45dc-bec5-fce7b2699448","acronym":"","url":"https://clinicaltrials.gov/study/NCT00217737","created_at":"2021-01-18T00:44:25.249Z","updated_at":"2025-02-25T14:39:13.469Z","phase":"Phase 3","brief_title":"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer","source_id_and_acronym":"NCT00217737","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • MSH2","pipe":"","alterations":" ","tags":["MSI • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3610","initiation":"Initiation: 09/06/2005","start_date":" 09/06/2005","primary_txt":" Primary completion: 08/31/2025","primary_completion_date":" 08/31/2025","study_txt":" Completion: 08/31/2025","study_completion_date":" 08/31/2025","last_update_posted":"2025-02-14"}]